Clinician's guide to hepatitis C

Area of Science:

• Hepatology
• Virology
• Public Health

Background:

• Hepatitis C virus (HCV) infection is a significant global health concern, frequently asymptomatic and leading to chronic liver disease, cirrhosis, and hepatocellular carcinoma.
• Mortality rates associated with chronic hepatitis C are projected to rise substantially, highlighting the urgent need for effective management and prevention strategies.
• Many infections remain undiagnosed due to a lack of awareness among both patients and healthcare providers, underscoring the importance of targeted screening.

Purpose of the Study:

• To emphasize the critical need for screening at-risk populations for Hepatitis C virus infection.
• To review current and emerging therapeutic strategies for managing chronic Hepatitis C.
• To highlight the disparity in public funding for Hepatitis C virus research compared to other viral infections like HIV.

Main Methods:

• Review of existing literature on Hepatitis C virus epidemiology, diagnosis, and treatment.
• Analysis of current therapeutic efficacy and projected advancements in antiviral agents.
• Comparison of funding models for viral disease research.

Main Results:

• Hepatitis C virus infection is common, chronic, and often asymptomatic, posing a significant risk for liver cirrhosis and cancer.
• Current interferon-based therapies offer limited sustained viral clearance (10-15%), with combination therapy (interferon and ribavirin) improving response rates to approximately 40%.
• Future treatments may involve novel agents like protease inhibitors and multi-drug regimens, similar to HIV therapy, but research funding remains a challenge.

Conclusions:

• Universal screening for Hepatitis C virus is recommended for all at-risk individuals, including those with transfusion history before 1992.
• Treatment outcomes for Hepatitis C virus are improving with combination therapies, and further advancements are anticipated.
• Increased public funding is crucial for accelerating the development of more effective Hepatitis C virus therapies and combating the growing burden of this disease.